Annual lung-cancer screening with a chest X-ray doesn’t reduce deaths from the disease as it offers no benefit for early detection, a study found.
Novartis AG won U.S. approval of its treatment for patients with advanced non-small cell lung cancer.
An experimental lung cancer drug from Eli Lilly & Co. increased survival among patients with advanced disease compared with those on chemotherapy alone, a study showed. The shares gained 2.6 percent.
Roche Holding AG’s Tarceva medicine extended the time patients with a certain kind of newly diagnosed lung cancer lived without their disease getting worse in a late-stage study.